Chemomab Therapeutics Ltd. Retained Earnings
Chemomab Therapeutics Ltd. (CMMB) had Retained Earnings of -$111.62 million as of 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-03-23
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$111.62M.
- 2025-06-30: Retained Earnings (Accumulated Deficit) -$108.00M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$102.62M.
- 2024-06-30: Retained Earnings (Accumulated Deficit) -$96.18M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2025-12-31 | -$111.62M 20-F · filed 2026-03-23 | |
| 2025-06-30 | -$108.00M 6-K · filed 2025-08-14 | |
| 2024-12-31 | -$102.62M 20-F · filed 2026-03-23 | |
| 2024-06-30 | -$96.18M 6-K · filed 2024-08-21 | |
| 2023-12-31 | -$88.68M 20-F · filed 2025-04-04 | |
| 2023-06-30 | -$80.54M 6-K · filed 2023-08-14 | |
| 2023-03-31 | -$72.57M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$63.82M 20-F · filed 2024-03-28 | |
| 2022-09-30 | -$55.55M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$47.47M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$41.28M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$36.17M 10-K · filed 2023-03-20 | |
| 2021-09-30 | -$31.14M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$28.17M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | -$25.40M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$23.70M 10-K · filed 2022-03-30 | -$117.04M 10-K · filed 2021-03-09 |
| 2020-09-30 | -$114.90M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | -$112.45M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | -$108.97M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$105.43M 10-K · filed 2021-03-09 | |
| 2018-12-31 | -$78.31M 10-K · filed 2020-03-17 |